| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Rapamycin | CTRPv2 | pan-cancer | AAC | 0.31 | 1e-08 |
| mRNA | MK-2206 | CTRPv2 | pan-cancer | AAC | 0.28 | 7e-07 |
| mRNA | OSI-906 | CTRPv2 | pan-cancer | AAC | 0.26 | 2e-06 |
| mRNA | NSC95397 | CTRPv2 | pan-cancer | AAC | 0.24 | 3e-06 |
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | -0.32 | 3e-06 |
| mRNA | AT-7519 | GDSC1000 | pan-cancer | AAC | 0.3 | 3e-06 |
| mRNA | PIK-93 | CTRPv2 | pan-cancer | AAC | 0.25 | 3e-06 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.24 | 7e-06 |
| mRNA | CAL-101 | GDSC1000 | pan-cancer | AAC | 0.31 | 1e-05 |
| mRNA | KIN001-102 | GDSC1000 | pan-cancer | AAC | 0.28 | 2e-05 |